FDA Publishes First Draft Guidance for Clinical Trials with Psychedelic Drugs

Last month, the Food and Drug Administration (“FDA” or “Agency”) published its first draft guidance for sponsors of clinical trials involving psychedelics. The draft guidance has been released amid the growing interest and research on psychedelics and their potential for therapeutic uses, such as in the treatment of psychiatric or substance use disorders. Psychedelics, according to the […]

Go to Source

Powered by WPeMatico